Periodic Reporting for period 1 - TechnocaP (Innovative technology for capsule filling machines to boost the pharmaceutical manufacturing process)
Reporting period: 2018-02-01 to 2018-05-31
In the first part, we analysed the status of the technology validation and performed some initial tests in real conditions after prototyping. As a result, we defined the work plan for the development of the new features into MG2 capsule filling machines for Phase 2.
In the second part, a summarized analysis of the target markets is presented for the main applications of TechnocaP in the pharmaceutical packaging market. The competing solutions and companies are introduced, and the value chain is shown. We included an update as well on the commercialization plan. The IP management strategy is explained and the results of the Freedom to Operate are summarized.
In the third part, a summary on the financial viability assessment is shown that establishes the budget necessary for the development of the MG2 machines, and the revenues and expenses projections for the next five years.
Finally, a brief risk analysis is included, covering commercial, technical, financial and legal risks.
TechnocaP will have an important impact in our business plan, expecting to increase more than 60% our market share push by our commercial department, US filial and extend network of 32 agents in 60 countries. During the Feasibility Study, we have estimated that we can grow the company to more than 230 employees, more than 30% growth rate. With a total investment of 1.8 million €, we expect a quick payback time after less than 3 years. MG2 will have a direct economic and social impact, strengthening the position of European companies in the capsule filling machine industry